Procept BioRobotics' Aquablation Therapy Shows Encouraging Five-Year Data In Prostate Gland Enlargement

Loading...
Loading...

Procept BioRobotics Corp PRCT announced five-year results from the WATER study comparing Aquablation therapy to TURP, the historical standard of care for treating benign prostatic hyperplasia (BPH).

  • Procept is a surgical robotics company that develops, manufactures, and sells the AquaBeam Robotic Surgical System for minimally-invasive urologic surgery with an initial focus on treating BPH.
  • The 181-subject study proved superior safety due to low irreversible complications and superior symptom relief for prostates in 50 milliliters or greater.
  • At five years, IPSS scores improved by 15.1 points in the Aquablation group and 13.2 points in TURP (p=.2764). 
  • However, for men with larger prostates greater than 50 milliliters, IPSS reduction was 3.5 points greater across all follow-up visits in the Aquablation group than the TURP group (p=.0123). 
  • The International Prostate Symptom Score (IPSS) is used to diagnose, track the symptoms, and suggest management of BPH symptoms.
  • Improvement in peak urinary flow rate was 125% and 89% compared to baseline for Aquablation and TURP, respectively. 
  • Retreatment rates, including BPH medication or surgical intervention, were approximately 1% per year for Aquablation, a 51% reduction compared to TURP.
  • Price Action: PRCT shares closed 0.20% higher at $20.01 on Monday.
Posted In: NewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...